PLoS ONE (Jan 2019)

Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus.

  • N Jiang,
  • M Li,
  • M Zhang,
  • J Xu,
  • L Jiang,
  • L Gong,
  • F Wu,
  • J Gu,
  • J Zhao,
  • Y Xiang,
  • Z Wang,
  • Y Zhao,
  • X Zeng,
  • CSTAR co-authors

DOI
https://doi.org/10.1371/journal.pone.0225516
Journal volume & issue
Vol. 14, no. 11
p. e0225516

Abstract

Read online

ObjectivesTo investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE).MethodsThe study was conducted based on the Chinese SLE Treatment and Research group (CSTAR) registry. Thrombocytopenia was defined as the platelet countResultsOf 2104 patients with SLE, 342 patients (16.3%) were diagnosed with thrombocytopenia. The prevalence of neuropsychiatric SLE, vasculitis, myositis, nephritis, mucocutaneous lesions, pleuritis, fever, leukocytopenia and hypocomplementemia were significantly higher in patients with thrombocytopenia (pConclusionsThrombocytopenia was a common manifestation of SLE and was associated with leukocytopenia, nephritis and severe disease activity. Severe thrombocytopenia tended to occur in long-term and relatively inactive SLE. Patients with SLE-related thrombocytopenia has a decreased long-term survival rate. Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia.